No Data
No Data
Calculating The Fair Value Of Kingchem (Liaoning) Life Science Co., Ltd. (SZSE:301509)
Jinkai Life Sciences (301509.SZ): focusing on developing European and Asia-Pacific customer base.
On September 11, Gelonghui reported that Jinkaiseng Science (301509.SZ) stated at an investor relations event that the company has been actively adjusting and has taken various measures, including: 1. Strengthening the BD team, fully leveraging the international BD team and customer resource advantages, focusing on developing customers in Europe and the Asia-Pacific region, actively expanding business increment on the basis of striving for existing customer project orders; 2. Fully leveraging the strategic support of the US GMP production base and R&D center, while hedging risks, quickly generating performance contributions from the base and introducing more projects; 3. Fully leveraging the pharmaceutical CDMO field
Kingchem: Half-year report for the year 2024.
Kingchem: Summary of Half-Year Report in 2024.
JinkaiShengke (301509.SZ) released its performance for the first half of the year, with a net income of 32.0917 million yuan, a decrease of 71.32%.
Jinkai Biosciences (301509.SZ) released its 2024 interim report, with a revenue of 0.262 billion...
Jinkai Biological (301509.SZ): The net income for the first half of the year was 32.0917 million yuan, a 71.32% year-on-year decrease.
Jinkai Life Sciences (301509.SZ) announced its semi-annual report for 2024, with revenue of 0.262 billion yuan, a decrease of 39.36% year-on-year; net income attributable to shareholders of the listed company was 32.0917 million yuan, a decrease of 71.32% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 24.505 million yuan, a decrease of 78.03% year-on-year; basic earnings per share was 0.27 yuan.
No Data
No Data